A woman who was among the early adopters of Wegovy’s new weight-loss medication shared her experience, noting that it significantly reduced her appetite to the extent that she sometimes forgot to eat. Sharon Vickers, aged 46, had been struggling with weight issues for an extended period and had previously undergone gastric sleeve surgery in January 2025, shedding 73lbs before hitting a weight loss plateau.
Having found GLP-1 injections costly and being reluctant to self-administer them, Sharon opted to try out the newly introduced Wegovy pill. Purchasing a 30-day supply, she observed renewed weight loss progress upon commencing its use.
Starting with a dosage of 1.5mg that was later increased to 4mg in April, Sharon expressed how the pill curbed her hunger pangs so effectively that she frequently missed meals. Consequently, on May 17, 2026, she began tapering off the pills after attaining her target weight of 175lbs and eventually discontinued their intake on May 27.
The United States premiered the pill in January 2026, followed by the United Arab Emirates in June, and recently gaining approval from UK authorities. Sharon mentioned, “It significantly reduced my appetite, and I was shedding about 2lbs weekly.” She further added, “Around the tenth day, I noticed a considerable decrease in my food intake and felt full much quicker, which wasn’t my original intention.”
Expressing her desire for the pill to aid in controlling food portions and reducing cravings rather than completely eradicating hunger, Sharon adopted an alternate-day regimen until hitting her milestone weight of 175 lbs on May 17. Subsequently, she initiated the weaning process and by May 27, she had successfully stopped using the medication.
Following her gastric sleeve surgery in January 2025, Sharon, who previously weighed 263lbs, lost 73lbs but struggled to shed more weight, hovering between 188lbs and 192lbs.
Regarding her exploration of GLP-1 injections in September, Sharon highlighted the exorbitant costs associated with them, stating, “The expense of weight loss injections was beyond my budget. Even the thought of self-injecting was daunting for me. Primarily, it was the financial aspect that deterred me from purchasing them.”
Prior to commencing the Wegovy pill, Sharon weighed 188lbs and has since reached 175lbs. Initially starting at 1.5mg, she transitioned to 4mg in April after noticing the initial dosage becoming less effective.
Expressing her satisfaction with the results, Sharon exclaimed, “I feel fantastic – like a whole new person. I have completed two half marathons, achieving a personal record in my latest one by 10 minutes. I can confidently say I am proud of my achievements and transformation.”
Achieving her weight goal on May 17, 2026, Sharon embarked on the process of gradually discontinuing the pills. As of May 27, she has completely stopped the medication and is currently focused on maintaining her weight loss.
Transitioning into a maintenance phase without the aid of GLP-1, Sharon acknowledged the challenges posed by cravings and temptations. Despite these hurdles, she remains dedicated to her six-day weekly workout routine with a supportive coach and contemplates the possibility of reverting to the Wegovy pill if necessary.
As Sharon aptly put it, “Only time will tell.”
